NEWS

The proposed expansion to the Inflation Reduction Act would substantially harm U.S. biopharma, triggering hundreds of thousands of job...

Pharmaceutical companies are delaying, or outright canceling, the development of new medicines following new drug rules signed into law...

The passage of last year’s Inflation Reduction Act (IRA) made major structural changes to the way Medicare covers and pays for...

Employers and unions are getting fed up with the firms they have used for years to help control their spending on prescription...

Clinical development programs for new drugs include an array of research conducted both before and after a drug’s initial approval by the...

Major drug companies are likely to ratchet up a sprawling legal attack aimed at challenging the Biden administration’s Medicare drug...

Demand for new lab space has plummeted by more than half since the end of 2021, and life science vacancy rates are the highest they’ve...

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the...

The U.S. Department of Health and Human Services (HHS) on Tuesday announced the first 10 drugs covered under Medicare Part D to be...

WASHINGTON — Medicare can now negotiate lower prices for 10 common high-price drugs, cutting out-of-pocket costs for an estimated 9...

Before a once-in-a-generation pandemic struck the globe, adalimumab (Humira; AbbVie) was the most profitable drug in the world...

By Reuters FRANKFURT (Reuters) -Roche said it had abandoned certain drug development projects or acquisitions under consideration...